The Stork OTC: Collection, Placement & Delivery

The Stork™ Conception System (OTC) Clinical Trial: Semen Collection, Placement and Delivery

This is a clinical study designed to validate the usability and safety of the over-the-counter (OTC) device by obtaining feedback in a home use environment regarding ease of use of The Stork™ Conception System and the instructions for use. In addition to usability, results for safety, including vaginal

Study Overview

• Status: Completed
• Conditions: Safety and Usability
• Intervention / Treatment: Device: The Stork - Conception Aid

Detailed Description

Female participants will undergo a baseline pelvic examination. Participating couples will be given The Stork™ Conception System (OTC), including Instructions for Use, the questionnaire and two ziplock bags. The device will be used in accordance with the instructions for use. Participants will use the Conceptacle as a collection condom during sexual intercourse. Participants will remove the Cervical Cap from the Sheath of the Conceptacle and discard the Sheath. Participants will then load the Cervical Cap into the Applicator for insertion, placement and deployment of the device. Participants will wash the applicator with soap and water and place it in the double zip lock bags. During the time the cervical cap is inserted, normal activity will be recommended with the exception of having intercourse. The female participants will leave the conception cap inserted for a period of time between 4 and 12 hours, return to the investigator's office for examination, remove the Cervical Cap, and undergo a follow up pelvic examination. Participants will be asked to complete the study and the questionnaire within 3 days of receiving the study packet. As a result, this study could take up to 4 days to complete per enrolled couple.

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Monroeville, Pennsylvania, United States, 15146
      • Forbes Regional Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Literacy must be in English (able to understand Informed Consent)
• In general good health
• Heterosexual, monogamous couples, of any race or ethnicity, who are sexually active (as a couple)
• 18 - 50 years of age
• REALM-SF Test Results demonstrate 6th grade literacy or above
• Past experience with using condoms
• Trying to conceive or using a non-vaginal birth control with which they do not normally use a condom.
• Signed Informed Consent

Exclusion Criteria:

• Vaginal prolapsed (female)
• Hysterectomy (female)
• Erectile Dysfunction (male)
• Colposcopy with biopsy surgery within the last three (3) months (female)
• Treatment for dysplasia surgery within the last three (3) months (female)
• Vaginal/cervical surgery within the last three (3) months (female)
• Current Pregnancy (female)
• Unable to read and understand English

Study Plan

How is the study designed?

Design Details

• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: The Stork; Device - The Stork - complete kit (Conceptacle and Applicator)	Device: The Stork - Conception Aid; Other Names: The Stork

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy -Primary endpoint part 1 - Collection	The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. The three parts of the endpoint are: P1: Participants indicate ability to collect and contain semen using the Conceptacle™. The examinations will occur 4-12 hours after device insertion.	1-3 days
Efficacy - Primary endpoint part 2 - Placement	The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. P2: Successful placement of the cervical cap as determined by physical examination.	4-12 hrs
Primary endpoint part 3 -Safety	The primary endpoint of the study is comprised of 3 parts. It is binary, in the sense that if all of the three parts are "passed" then the endpoint is met for that couple. If any part of the endpoint is not met then the endpoint for that couple is not met. P3: Participants use the device without any evidence of damage to the female participants' genital tract as depicted by physician examination.	4-12 hrs

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Endpoint	Secondary Objectives: Pass/Fail Answers to the specific questions Male 1-3 and Female 1-4 on the CRF will be compiled descriptively to indicate participant success during the study.	up to 3 days

Collaborators and Investigators

• Sponsor: Rinovum Women's Health, Inc.
• Investigators: Principal Investigator: Michael J Pelekanos, OB-GYN, Forbes Regional Hospital

Study record dates

Study Major Dates

• Study Start: July 1, 2013
• Primary Completion (Actual): January 1, 2014
• Study Completion (Actual): January 1, 2014

Study Registration Dates

• First Submitted: October 28, 2013
• First Submitted That Met QC Criteria: January 15, 2014
• First Posted (Estimate): January 16, 2014

Study Record Updates

• Last Update Posted (Estimate): January 16, 2014
• Last Update Submitted That Met QC Criteria: January 15, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Keywords: OTC Home Use Conception Aid Cervical Cap Insemination
• Other Study ID Numbers: ER-000025